Sotagliflozin is under clinical development by Lexicon Pharmaceuticals and currently in Pre-Registration for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Pre-Registration drugs for Type 1 Diabetes (Juvenile Diabetes) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Sotagliflozin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sotagliflozin overview
Sotagliflozin (Zynquista, Inpefa) is a potential antihyperglycemic agent. It is formulated as film coated tablets for oral route of administration. Zynquista is indicated as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy.
Sotagliflozin (LX4211, SAR-439954) is under development for the treatment of type 2 diabetes, diabetic kidney disease, type 1 diabetes who have CKD and hypertrophic cardiomyopathy. It was also under development for the treatment of worsening of heart failure in diabetic patients in the US.
Lexicon Pharmaceuticals overview
Lexicon Pharmaceuticals (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. Lexicon is focusing on the introduction of its approved medication, Inpefa (sotagliflozin), into the market specifically for the treatment of heart failure. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for hypertrophic cardiomyopathy (HCM) and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.
For a complete picture of Sotagliflozin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
